浏览全部资源
扫码关注微信
1.重庆医科大学附属第三医院药剂科,重庆 401120
2.重庆市药品不良反应监测中心,重庆 401120
药师,硕士。研究方向:临床药学、药物不良反应。E-mail:15123054472@163.com
主管药师。研究方向:临床药学、药物警戒。E-mail:650101@hospital.cqmu.edu.cn
纸质出版日期:2023-09-30,
收稿日期:2023-03-17,
修回日期:2023-07-07,
扫 描 看 全 文
陈诚,王彦,邓莉等.重庆市2015-2022年药物过敏性休克救治使用肾上腺素情况的回顾性研究 Δ[J].中国药房,2023,34(18):2238-2242.
CHEN Cheng,WANG Yan,DENG Li,et al.Retrospective study on the use of epinephrine in patients with drug-induced anaphylactic shock in Chongqing from 2015 to 2022[J].ZHONGGUO YAOFANG,2023,34(18):2238-2242.
陈诚,王彦,邓莉等.重庆市2015-2022年药物过敏性休克救治使用肾上腺素情况的回顾性研究 Δ[J].中国药房,2023,34(18):2238-2242. DOI: 10.6039/j.issn.1001-0408.2023.18.12.
CHEN Cheng,WANG Yan,DENG Li,et al.Retrospective study on the use of epinephrine in patients with drug-induced anaphylactic shock in Chongqing from 2015 to 2022[J].ZHONGGUO YAOFANG,2023,34(18):2238-2242. DOI: 10.6039/j.issn.1001-0408.2023.18.12.
目的
2
评价肾上腺素在药物过敏性休克救治中使用的合理性,为进一步规范过敏性休克的救治提供参考。
方法
2
依据重庆市药品不良反应(ADR)监测中心提供的2015-2022年药物过敏性休克严重ADR报告的相关数据,回顾性分析患者的救治药物选择及肾上腺素使用情况,探讨不同肾上腺素救治方案下过敏性休克患者的临床转归情况。
结果
2
共纳入1 415份药物过敏性休克严重ADR报告,所涉患者男女比例为1.04∶1;引发过敏性休克的药物主要为抗感染药(47.92%)、中药注射剂(9.12%);43.96%患者的ADR发生于用药后10 min内;97.24%的患者治愈或好转,2.76%的患者死亡或未好转。1 415例患者中,使用肾上腺素救治的占63.39%,首选肾上腺素救治的占53.14%;肌内注射、皮下注射、静脉注射和静脉滴注分别占33.78%、30.32%、25.75%和1.23%;肾上腺素的初始剂量范围为0.01~10 mg,单次剂量以1 mg居多(44.70%);肌内注射、皮下注射和静脉注射单次剂量过量的分别有148例(51.03%)、136例(53.13%)和193例(91.47%),静脉注射给药更有可能出现单次剂量过量(
P
<0.05)。初始救治使用肾上腺素者的好转/痊愈率显著高于非肾上腺素使用者(98.14% vs. 96.23%,
P
=0.029),首选肾上腺素者的好转/痊愈率显著高于非首选肾上腺素者(98.14% vs. 95.17%,
P
=0.031),肌内注射者的好转/痊愈率显著高于非肌内注射者(99.01% vs. 96.69%,
P
=0.038)。
结论
2
在药物过敏性休克的救治中,存在救治药物选择不适宜和肾上腺素使用不足、给药延迟、给药途径不适宜及单次剂量过高等不合理现象。
OBJECTIVE
2
To evaluate the rationality of epinephrine in the treatment of drug-induced anaphylactic shock, and to provide a reference for further standardizing the treatment measures of anaphylactic shock.
METHODS
2
According to the relevant data of the reports of severe adverse drug reaction (ADR) of drug-induced anaphylactic shock provided by Chongqing ADR Monitoring Center from 2015 to 2022, the selection of treatment drugs, and the application of epinephrine in anaphylactic shock were analyzed retrospectively; the clinical outcomes of anaphylactic shock with different epinephrine administration methods were investigated.
RESULTS
2
A total of 1 415 cases of severe ADR related to drug-induced anaphylactic shock were reported, with a male-to-female ratio of 1.04∶1; the drugs that caused allergic shock mainly included anti-infective drugs (47.92%), TCM injections (9.12%); the patients who suffered from drug-induced anaphylactic shock within 10 min after medication accounted for 43.96%; 97.24% of patients were cured or improved, and 2.76% of patients died or did not been improved. Among 1 415 patients, 63.39% of patients were treated with epinephrine, and the patients who preferred epinephrine treatment accounted for 53.14%; the intramuscular injection, subcutaneous injection, intravenous injection and intravenous drip accounted for 33.78%, 30.32%, 25.75% and 1.23%, respectively. The initial dose range of epinephrine was 0.01-10 mg, and the most frequent single dose was 1 mg (44.70%). Excessive single doses of intramuscular injection, subcutaneous injection and intravenous injection accounted for 51.03% (148 cases), 53.13% (136 cases) and 91.47% (193 cases) respectively, and the risk of overdose in intravenous injection was higher (
P
<0.05). The patients receiving initial treatment with epinephrine had a higher improvement rate/cure rate than those who did not use epinephrine (98.14% vs. 96.23%,
P
=0.029); the patients who preferred epinephrine had a higher improvement rate/cure rate than those who did not preferred epinephrine (98.14% vs. 95.17%,
P
=0.031); the improvement rate/cure rate of patients receiving intramuscular injection of epinephrine was higher than those without intramuscular injection (99.01% vs. 96.69%,
P
=0.038).
CONCLUSIONS
2
There are some unreasonable phenomena in the treatment of drug-induced anaphylactic shock, such as inappropriate selection of drugs, insufficient use of epinephrine, delay of administration, inappropriate route of administration and excessive single dose.
肾上腺素药物过敏性休克用药分析不良反应
drug-induced anaphylactic shockanalysis of drug useadverse drug reaction
刘峰,刘锐锋. 191例药物致过敏性休克不良反应文献分析[J]. 中国药房,2013,24(30):2854-2856.
CARDONA V,ANSOTEGUI I J,EBISAWA M,et al. World allergy organization anaphylaxis guidance 2020[J]. World Allergy Organ J,2020,13(10):100472.
李晓桐,翟所迪,王强,等. 《严重过敏反应急救指南》推荐意见[J]. 药物不良反应杂志,2019,21(2):85-91.
MURARO A,ROBERTS G,WORM M,et al. Anaphylaxis:guidelines from the European academy of allergy and clinical immunology[J]. Allergy,2014,69(8):1026-1045.
张崇,钟磊,赵珊珊,等. 病区急救车上配备药品的品种和数量优化方案探讨[J]. 中国药房,2018,29(11):1573-1576.
MCHUGH K,REPANSHEK Z. Anaphylaxis:emergency department treatment[J]. Emerg Med Clin North Am,2022,40(1):19-32.
JIANG N N,YIN J,WEN L P,et al. Characteristics of anaphylaxis in 907 Chinese patients referred to a tertiary allergy center:a retrospective study of 1 952 episodes[J]. Allergy Asthma Immunol Res,2016,8(4):353-361.
WANG T S,MA X,XING Y,et al. Use of epinephrine in patients with drug-induced anaphylaxis:an analysis of the Beijing pharmacovigilance database[J]. Int Arch Allergy Immunol,2017,173(1):51-60.
黄雅群,文睿婷,于芝颖,等. 哌拉西林及其复方制剂致过敏性休克的病例报道及文献分析[J]. 中国药房,2021,32(1):82-87.
郭代红,王伟华,杨鸿溢,等. 大样本住院人群中严重过敏样反应的信息化自动监测与救治用药分析[J]. 中南药学,2019,17(10):1608-1613.
褚燕琦,王之舟,刘琛,等. 25例药物过敏性休克肾上腺素救治再评价[J]. 中国药物应用与监测,2019,16(2):93-95.
SIMONS F E. Pharmacologic treatment of anaphylaxis:can the evidence base be strengthened?[J]. Curr Opin Allergy Clin Immunol,2010,10(4):384-393.
CAMPBELL R L,LI J T,NICKLAS R A,et al. Emergency department diagnosis and treatment of anaphylaxis:a practice parameter[J]. Ann Allergy Asthma Immunol,2014,113(6):599-608.
滕威,逄晓云. 某三甲医院2009年至2019年药物相关过敏性休克报告分析与救治[J]. 中国药物警戒,2022,19(2):196-199.
汤春艳,汪小海,陈洁,等. 围手术期过敏性休克药物治疗研究进展[J]. 医药导报,2021,40(11):1506-1510.
BĂLAN H,GURGHEAN A. Anaphylactic shock:are we doing enough and with the right timing and order?[J]. Rom J Intern Med,2015,53(3):191-198.
司继刚,段磊,赵群,等. 肾上腺素救治过敏性休克使用方法调查分析[J]. 中国现代应用药学,2021,38(6):744-748.
GOODALL N. Guideline review:epinephrine use in anaphylaxis(AAP guideline 2017)[J]. Arch Dis Child Educ Pract Ed,2020,105(1):38-40.
盖迎利,冯莉. 肾上腺素在过敏性休克抢救中的应用[J]. 实用心脑肺血管病杂志,2011,19(6):1015.
0
浏览量
6
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构